Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening
Pharmaceuticals · 08.02.2024 · 17 (2) · 225
DOI: 10.3390/ph17020225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.02.2024. Verfasst von Xinxin Rao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Key Clinical Specialty Project of Shanghai., Key Clinical Specialty Project of Shanghai.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In this study, we established two patient-derived TNBC organoids and implemented a high-throughput drug screening system using these organoids and two TNBC cell lines. Screening a library of 169 epigenetic compounds, we found that organoid-based systems offer remarkable precision in drug response assessment compared to cell-based models. The top 30 compounds showing the highest drug sensitivity in the initial screening were further assessed in a secondary screen. Four compounds, panobinostat, pacritinib, TAK-901, and JIB-04, targeting histone deacetylase, JAK/STAT, histone demethylases, and aurora kinase pathways, respectively, exhibited potent anti-tumor activity in TNBC organoids, surpassing the effect of paclitaxel. Our study highlights the potential of these novel epigenetic drugs as effective therapeutic agents for TNBC and demonstrates the valuable role of patient-derived organoids in advancing drug discovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China.
ORCID-Profile: Xinxin Rao, Xiaomao Guo
Förderung
- the Key Clinical Specialty Project of Shanghai.
- Key Clinical Specialty Project of Shanghai
Zitieren
APA
Rao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., & Guo, X. (2024). Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening. Pharmaceuticals, 17(2), 225. https://doi.org/10.3390/ph17020225
Vancouver
Rao X, Qiao Z, Yang Y, Deng Y, Zhang Z, Yu X, et al. Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening. Pharmaceuticals. 2024;17(2):225. doi:10.3390/ph17020225
BibTeX
@article{Rao2024,
author = {Rao, Xinxin and Qiao, Zhibin and Yang, Yang and Deng, Yun and Zhang, Zhen and Yu, Xiaoli and Guo, Xiaomao},
title = {Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {2},
pages = {225},
doi = {10.3390/ph17020225}
}
EUVIMED